The global CD Antigen Cancer Therapy Market is valued at USD 27.5 Billion in 2024 and is projected to reach a value of USD 54 ...

OXFORD, UK I April 9, 2025 I Infinitopes Ltd today announces that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Clinical Trial ...

H3, a key cancer antigen and immune checkpointHighly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer ...

“Building on decades of research into the genetic markers of prostate cancer, our study shows that the theory does work in ...

A new at-home saliva test for prostate cancer could outperform current testing methods, a new study suggests. Researchers ...

Breast Cancer Animal Studies Show Unprecedented Anti-Cancer Efficacy of 100% Tumor Growth Inhibition HONG KONG, CHINA / ACCESS Newswire / April 11, 2025 / CK Life Sciences Int'l., (Holdings) Inc. ("CK ...

Cancer diagnoses traditionally require invasive or labor-intensive procedures such as tissue biopsies. Now, research ...

PGV001, a personalized cancer vaccine, induced immune responses across various cancer types like breast and urothelial cancer ...

Epsilogen’s earlier stage pipeline also features a number of other IgE antibody candidates targeting a variety of tumour antigens. Epsilogen is the world’s leading pan-isotype antibody ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Epsilogen’s earlier stage pipeline also features a number of other IgE antibody candidates targeting a variety of tumour antigens. TigaTx is a biotechnology company developing engineered ...